All In Biotech

Drug Trial Radar · NCT06399289

Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX Therapy

A Phase 3, Open-label, Multicenter, Pharmacokinetics, Efficacy, and Safety Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Previously Treated Chinese Subjects With Hemophilia B

Last checked: Nov 20, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

23

Actual

Start

Jul 28, 2024

Primary completion

Jul 7, 2026

Study completion Jul 7, 2026

Sponsor

Lead sponsor
CSL BehringIndustry
Sponsor type
Industry
First posted
May 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Male only, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will investigate the pharmacokinetics (PK), efficacy, and safety of rIX-FP for the routine prophylaxis of bleeding episodes in male Chinese previously treated patients (PTPs) with hemophilia B (FIX activity of ≤ 2%). In addition to the scheduled rIX-FP prophylaxis regimen, subjects may also receive rIX-FP episodic (on-demand) treatment for breakthrough bleeding episodes and rIX-FP for the prophylaxis and treatment of bleeding in emergency surgical procedures.

Conditions

  • Hemophilia B

Interventions

  • Recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP)Biological

    Lyophilized powder for solution for intravenous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incremental recovery (IR) (plasma FIX activity)Time frame: Before, and at 30 minutes after the end of, rIX-FP infusion on Day 1
  2. Maximum plasma concentration (Cmax)Time frame: Before, and up to 336 hours after the end of, rIX-FP infusion on Day 1
  3. Terminal elimination half-life (t1/2) of rIX-FPTime frame: Before, and up to 336 hours after the end of, rIX-FP infusion on Day 1
  4. Area under the concentration-time curve (AUC)Time frame: Before, and up to 336 hours after the end of, rIX-FP infusion on Day 1
  5. Clearance (Cl) of rIX-FPTime frame: Before, and up to 336 hours after the end of, rIX-FP infusion on Day 1
  6. Annualized spontaneous bleeding rate (AsBR)Time frame: Up to 18 months
  7. Number of subjects who develop an inhibitor to FIXTime frame: Up to 18 months after rIX-FP infusion

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Children's Hospital

    Beijing, Beijing Municipality, China

  • Union Hospital Affiliated to Fujian Medical University

    Fuzhou, Fujian, China

  • Nanfang Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, China

  • North China University Of Science And Technology Affiliated Hospital

    Tangshan, Hebei, China

  • Jinan Central Hospital

    Jinan, Shandong, China

  • Hospital of Hematology, Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.